Pettit, MD, discussed the potential of using treatment earlier in polycythemia vera to alter the disease course. During a ...
The treatment landscape for newly diagnosed multiple myeloma (NDMM) has transformed rapidly in recent years, with quadruplet regimens now dominating both guideline recommendations and clinical ...
Rd, reaching 76.1% at 60 months versus 40.0% with VRd/Rd, and continues rising post-bortezomib discontinuation. Conversion ...
He also reviews the development of menin inhibitors in AML, including recent regulatory advances in the relapsed/refractory ...
Narjust Florez, MD, a thoracic medical oncologist at Dana-Farber Cancer Institute, discusses the clinical and structural gaps ...
The standard of care established in the early 2000s is, in most respects, still the standard of care today—a fact that ...
Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and ...
ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides ...
NCCN now endorses CSF-based profiling for biopsy-infeasible HGG/GBM to enable molecular characterization required for ...
The FDA has approved capivasertib (Truqap) in combination with abiraterone acetate (Zytiga) and prednisone for adults with ...
FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and ...
Real-world prescribing lagged behind current intent, with post-review voting favoring taletrectinib over repotrectinib and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results